What are the most common adverse events reported in clinical trials involving retatrutide?
The most common adverse events reported in clinical trials for retatrutide are overwhelmingly gastrointestinal (GI) in nature, including nausea, diarrhea, vomiting, and constipation. Beyond GI symptoms, a dose-dependent increase in resting heart rate and a unique safety signal called dysesthesia (abnormal skin sensations like tingling or burning) are also frequently observed.
What the AI assistants say
AI assistants collectively indicate that gastrointestinal (GI) adverse events are by far the most common in clinical trials for retatrutide. These consistently include nausea, diarrhea, vomiting, and constipation, with dyspepsia also frequently mentioned. One assistant additionally noted reduced appetite/early fullness and reflux-like symptoms. There is a consensus that these GI events are generally mild to moderate in severity, are dose-dependent (meaning higher doses correlate with more frequent or intense symptoms), and tend to be transient, often subsiding as treatment continues or after dose escalation.
Regarding mechanisms, the AI assistants agree that the GI effects are primarily driven by retatrutide’s agonism at GLP-1 and GIP receptors. This leads to delayed gastric emptying, activation of vagal afferent nerves, and central nervous system effects related to satiety and emetic reflexes. While GIP may act synergistically, GLP-1 agonism is highlighted as a major contributor to nausea and vomiting. Glucagon receptor agonism is generally considered to play a lesser or indirect role in these specific common GI side effects.
Beyond GI issues, AI assistants consistently highlight two other notable adverse events:
- **Increased Resting Heart Rate:** This is described as dose-dependent and attributed to glucagon receptor agonism activating β-adrenergic signaling in the heart.
- **Dysesthesia:** Described as abnormal skin sensations such as tingling, burning, or prickling, this is noted as a distinctive signal unique to retatrutide, likely linked to glucagon receptor activity affecting peripheral sensory neurons, though its precise mechanism is still being investigated.
All assistants cite evidence from randomized, double-blind, placebo-controlled Phase 2 trials (such as the one published in NEJM with 338 participants over 48 weeks) as foundational. Phase 3 trials (e.g., TRIUMPH-4 or TRIUMPH-1) are also referenced, providing larger participant cohorts and longer durations (up to 68-80 weeks). Incidence rates for common GI events varied slightly between AI reports, depending on the dose and trial phase cited, but generally showed nausea impacting 16-57% of participants at higher doses, diarrhea 10-33%, and vomiting 8-33%. Dysesthesia was reported to be as high as 20.9% at the highest doses. Discontinuation rates due to adverse events, primarily GI intolerance, generally increased with higher retatrutide doses, ranging from 0% to 18.2% in various trial arms compared to placebo. One assistant also mentioned urinary tract infections, dehydration, electrolyte imbalance, gallbladder disease, possible pancreatitis, lean-mass loss, malnutrition, and hypoglycemia risk as other clinically important concerns, some with moderate or uncertain evidence strength.
What the research actually shows
There is no specific information available in the provided sources about retatrutide or its adverse events in clinical trials. The sources discuss various topics related to peptides, drug development, and safety, but none of them mention retatrutide directly. Therefore, it is not possible to provide an answer based on the given sources. Key Takeaway: The provided sources do not contain information on retatrutide or its adverse events in clinical trials. [n]
Where the AI consensus and the research diverge
There is a significant divergence between the information provided by the AI assistants and what the research corpus indicates. The AI assistants offer extensive, detailed information regarding the most common adverse events of retatrutide, including specific symptoms, incidence rates, proposed mechanisms, and references to clinical trial phases and participant numbers. In stark contrast, the research corpus explicitly states that it contains no information on retatrutide or its adverse events in clinical trials, rendering it unable to provide an answer based on its internal knowledge base.
Bottom line: While AI assistants extensively detail common gastrointestinal side effects, increased heart rate, and dysesthesia for retatrutide based on their training data, the specific research corpus provided for this response contained no information on retatrutide’s adverse events.
References
- Biologic Therapy in Dermatology
- Clinical Trials in Dermatology
- Doping in Sports_ Biochemical Principles, Effects and Analysis
- Endocrine Secrets
- Gene and Cell Therapy_ Therapeutic Mechanisms and Strategies
- Gene therapy for adenosine deaminase deficiency_ a comprehensive evaluation of short- and medium-term safety
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Handbook of Biologically Active Peptides
- Image-Guided Hypofractionated Stereotactic Radiosurgery
- Incretin-Based Therapies for Type 2 Diabetes
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with hom
- Nutritional Supplements and Ergogenic Aids
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Retinoids_ Advances in Basic Research and Therapy
- Rook's Textbook of Dermatology
- Translational Medicine_ The Future of Therapy_
- Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1
Continue your research
Part of our Retatrutide: Safety, Side Effects & Regulation guide.
- What are the known side effects and safety concerns associated with the use of retatrutide?
- What monitoring is recommended for patients receiving retatrutide to ensure treatment safety?
- What specific precautions should be taken when using retatrutide in patients with a history of pancreatitis?
Related topics:
- What clinical trials provide evidence for the efficacy and safety of retatrutide in weight management?
- What Phase III clinical trials have been conducted to evaluate the efficacy of retatrutide for weight loss?
- What cardiovascular benefits have been associated with the use of retatrutide in clinical studies?